Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
about
Development of targeted therapies in treatment of glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingContemporary murine models in preclinical astrocytoma drug developmentCase-specific potentiation of glioblastoma drugs by pterostilbeneGefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastomaHigh cytoplasmic FOXO1 and pFOXO1 expression in astrocytomas are associated with worse surgical outcome.The challenges and the promise of molecular targeted therapy in malignant gliomas.Novel therapies in glioblastoma.Current trends in targeted therapies for glioblastoma multiformeThe Globalization of Cooperative Groups.Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challengesCombining molecular targeted agents with radiation therapy for malignant gliomasAutotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell LinesThe molecular basis for novel therapies.Using the molecular classification of glioblastoma to inform personalized treatment.Molecular pathways and potential therapeutic targets in glioblastoma multiforme.Targeted therapy in gliomas.Glioblastoma multiforme: State of the art and future therapeutics.State of the art and perspectives in the treatment of glioblastoma.Predictive biomarkers investigated in glioblastoma.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Molecular targets in glioblastoma.Recent advances in targeted therapy for glioblastoma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Glioma Subclassifications and Their Clinical Significance.Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.Investigational new drugs for brain cancer.PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.Treatment options for recurrent high-grade gliomas.Biomarkers classification and therapeutic decision-making for malignant gliomas.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Safety, Pharmacokinetics and Antitumor Response of Depatuxizumab Mafodotin as Monotherapy or in Combination with Temozolomide in Patients with Glioblastoma.Genomic alterations of ERBB receptors in cancer: clinical implications.Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
P2860
Q26778787-4D3378D9-19F7-4A3B-AAB6-64C467EB8868Q26822717-3FF9B840-EDA5-41B7-B6F6-3DE34B73897CQ26829873-1BF8C093-7C5C-46D2-BED8-4DC718C5F583Q26862516-BE123D0E-3FB4-44EB-8DF5-305C9CA64833Q27011423-7C7EFE1F-2991-4254-B84A-907B378C5CB6Q27026937-D8AF4C42-401B-447C-8AC3-6EBABC677AA1Q29048651-79DFCA9D-9C47-4981-ABC0-82F5B4EF3DE4Q30541574-1535BED1-EF57-43D2-8478-56ED9D325519Q34853582-DC3BBCF5-211F-4ADE-A075-508F1C08D072Q35214534-D19904DF-FD06-4598-981A-B94B4027ACB9Q35864136-56DA292D-D087-470D-B90D-64D0B36313A3Q35864226-1A4778B2-76AF-412E-8FC9-6998A5FA137BQ36119749-691A1F5D-104C-40B3-A7B1-02B86092F15FQ36459981-7AEB51F9-4901-42C1-BAB4-A225EFDBB95EQ36524716-4B067973-8B41-43A7-9D33-95C13F153487Q37099594-E11C39BE-7099-4CAA-893A-3E24970495A4Q37177631-F2F7133B-E057-4B70-AE8F-173D6E9460B3Q37980023-DD8B066F-3B2A-47CA-BC38-78D68DF5DADFQ38151582-7A2DCA39-E168-42DF-B36C-10D354C89F5FQ38156191-8674E380-E1F4-496D-9706-CC058554E04BQ38186656-F415F6C3-54E2-43B5-AFAC-63739116BCFEQ38225874-9EF9047B-6734-4809-B408-56C1EA5A4BD4Q38233067-A152D96D-971B-425E-B0D8-15BE06500E9BQ38237337-CBF989B9-C38A-4931-9E6E-E0F29121C27EQ38351134-8E063154-4A21-4B70-A0F2-3947239C66F7Q38465854-62DA8414-D69D-4393-A9A6-6D8684B57910Q38539386-E1D5614A-26D2-4E85-BCEF-81125B211BA2Q38597700-9A594D68-33EE-46E9-BAD8-2174434C0360Q38694765-597A6807-F1E4-4338-BF2A-B9104D2BC320Q38720644-455D6E99-E46F-4118-9A69-18DB25307216Q38747746-39CF2241-23FD-4DBD-98E7-70B0C8F28FB6Q38776733-A7CE8BA9-7C20-457C-A797-9A1FABB7CC4DQ38832510-EA8819C2-6389-4223-A201-E669C7DAFAFAQ38888799-D4F8D00B-40F2-4A7F-9B35-A769C6167B7AQ39045968-5686C99E-518E-4050-A066-791B4349F875Q39556985-6BEC05E1-DCAF-451F-B95E-FB5E168897B0Q40089704-2EBCBFA8-DD20-447B-A0A6-DD8B8F5ACC32Q46051213-A9CCC30C-9E68-467B-8620-B7CBEBF68686Q49678076-888CA54F-9986-4327-81F9-27DA245CF4D0Q55412024-D481BC3B-526F-4784-85B3-BD82C5DC61B8
P2860
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@en
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@nl
type
label
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@en
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@nl
prefLabel
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@en
Phase II evaluation of gefitin ...... r Treatment Group Study N0074.
@nl
P2093
P2860
P1476
Phase II evaluation of gefitin ...... er Treatment Group Study N0074
@en
P2093
Bernd W Scheithauer
Caterina Giannini
J C Krauss
Jan C Buckner
Joon H Uhm
Kurt A Jaeckle
Patrick J Flynn
Paul L Schaefer
Robert J Behrens
P2860
P304
P356
10.1016/J.IJROBP.2010.01.070
P407
P577
2010-05-25T00:00:00Z